MARKET

BMY

BMY

Bristol-Myers Squibb Co
NYSE
60.07
-0.22
-0.36%
Opening 09:43 03/09 EDT
OPEN
59.55
PREV CLOSE
60.29
HIGH
60.26
LOW
59.55
VOLUME
556.19K
TURNOVER
--
52 WEEK HIGH
62.89
52 WEEK LOW
41.88
MARKET CAP
122.33B
P/E (TTM)
17.36
1D
5D
1M
3M
1Y
5Y
1D
Balanced Outlook on BMY: Positive Mezigdomide Phase III Data Support CELMoD Platform, but Long-Term Execution Risks Warrant Hold Rating
TipRanks · 4h ago
Bristol Myers Squibb Announces Positive Phase 3 Results For Mezigdomide In Multiple Myeloma
NASDAQ · 5h ago
Bristol Myers Squibb Says Blood-Cancer Treatment Performed Well in Late-Stage Trial
Dow Jones · 6h ago
Bristol Myers cancer drug meets main goal in late-stage study
Seeking Alpha · 6h ago
Bristol Myers reports ‘positive’ Phase 3 results from SUCCESSOR-2 study
TipRanks · 6h ago
Bristol Myers Squibb Reports Late-Stage Trial Results for Multiple Myeloma Drug
Benzinga · 6h ago
FDA plans to relax testing rules to encourage biosimilar drugs: report
Seeking Alpha · 7h ago
Weekly Report: what happened at BMY last week (0302-0306)?
Weekly Report · 7h ago
More
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

Webull offers Bristol-Myers Squibb Co stock information, including NYSE: BMY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMY stock methods without spending real money on the virtual paper trading platform.